Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes
Celcuity Inc. shares surged close to 16% Monday, after the Minneapolis-based biotech announced late Friday its lead drug candidate, gedatolisib, hit the primary endpoint in a late-stage breast cancer trial for patients with PIK3CA-mutant tumors. That news brought back attention to a July FDA decision and a planned cancer conference update in June for CELC stock.
